Brontictuzumab Completed Phase 1 Trials for Relapsed or Refractory Lymphoid Malignancies Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01703572A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies